Picture EBD Group ChinaBio Partnering Forum 2020 Digital Event CBPF2020 650x80
Person › Details

David Dible (Citigate Dewe Rogerson Ltd.)

Dible, David (Huntsworth 201506 Senior Director Life Sciences at Citigate Dewe Rogerson London)


Organisation Organisation Citigate Dewe Rogerson Ltd.
  Group Huntsworth (Group)
Product Product public relations / investor relations / marcom (services)

Clavis Pharma ASA. (1/11/11). "Press Release: Successful Completion of Subsequent Offering [ NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN ]". Oslo.


Clavis Pharma ASA (OSE: CLAVIS), reference is made to the announcement on 18 November 2010 and the prospectus dated 10 December 2010 concerning the subsequent offering of up to 600,000 shares in Clavis Pharma at a subscription price of NOK 35.

The subsequent offering ended on Monday 10 January 2011 at 17.30 CET, and was significantly oversubscribed. As a result, Clavis Pharma will issue 600,000 new shares at NOK 35 per share raising gross proceeds of NOK 21 million.

All subscribers being allotted offer shares will receive a letter confirming the number of offer shares allotted to the subscriber and the corresponding amount to be paid. This letter is expected to be distributed today.

Payment of shares will fall due on 14 January 2011 and delivery will take place on or about 19 January 2011. Following registration of the shares the total number of issued shares will increase by 600,000, from 29,761,650 to 30,361,650 shares.

The offering is managed by ABG Sundal Collier Norge ASA and Carnegie ASA.

For further information contact:

Olav Hellebø
Chief Executive Officer
Office: +47 24 11 09 50

Gunnar Manum
Chief Financial Officer
Office:+47 24 11 09 71
Mobile: +47 95 17 91 90

Mark Swallow / Nina Enegren / David Dible
Citigate Dewe Rogerson
Office:+44 207 282 2948

About Clavis Pharma

Clavis Pharma ASA is a clinical stage oncology discovery and drug development company based in Oslo, Norway with a portfolio of novel anti-cancer drugs in development. These patented New Chemical Entities (NCEs) are novel, improved versions of commercially successful drugs, made using Clavis Pharma's Lipid Vector Technology (LVT) chemistry. Data generated suggests these potential breakthrough products may offer improved efficacy and reduced side effects through enhanced pharmacokinetic properties, greater tissue penetration, altered metabolism and, in certain cases, additional modes of action.

Clavis Pharma's has several drug candidates in formal development studies:

> Elacytarabine, a leukaemia drug, currently in a randomized, controlled Phase III study in late-stage acute myeloid leukaemia;
> CP-4126, is currently in a Phase II comparative study with gemcitabine for the treatment of pancreatic cancer;
> CP-4200, an azacitidine derivative, in preclinical development for myelodysplastic syndrome (MDS), a disease that is often a precursor to leukaemia.

Clavis Pharma intends to commercialise its products through strategic alliances and partnerships with experienced oncology businesses and, where and when commercially appropriate, by establishing its own sales and marketing capabilities. CP-4126 is licensed to Clovis Oncology globally. Clavis Pharma has an option to co-promote CP-4126 in Europe.


The information contained herein shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities referred to herein in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration, exemption from registration or qualification under the securities laws of any such jurisdiction.

This news release contains forward-looking statements and forecasts based on uncertainty, since they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on results of operations and the financial condition of Clavis Pharma. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements. Theses factors include, among other things, risks associated with technological development, the risk that research & development will not yield new products that achieve commercial success, the impact of competition, the ability to close viable and profitable business deals, the risk of non-approval of patents not yet granted and difficulties of obtaining relevant governmental approvals for new products.

No expressed or implied representations or warranties are given concerning Clavis Pharma or the accuracy or completeness of the information or projections provided herein, and no claims shall be made by the recipient hereof by virtue of the information or projections contained herein. Clavis Pharma is a registered trademark of Clavis Pharma ASA.

Record changed: 2020-07-23


Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81

More documents for David Dible

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture Kentro Design Corporate and Web Design Berlin 650x65px

» top